International Burden of Illness Most cancers Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. International, regional, and nationwide most cancers incidence, mortality, years of life misplaced, years lived with incapacity, and disability-adjusted life-years for 32 most cancers teams, 1990 to 2015: a scientific evaluation for the International Burden of Illness Research. JAMA Oncol. 2017;3:524–48. https://doi.org/10.1001/jamaoncol.2016.5688
Simon H (ed). The Harvard Medical College Information to Males’s Well being: Classes from the Harvard Males’s Well being Research. New York: The Free Press and colophon are registered logos of Simon & Schuster, Inc; 2004.
Pourmand G, Salem S, Mehrsai A, Lotfi M, Amirzargar MA, Mazdak H, et al. The danger components of prostate most cancers: a multicentric case-control research in Iran. Asian Pac J Most cancers Prev. 2007;8:422–8.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. International most cancers statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. International most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660
Pinsky PF, Prorok PC, Yu Okay, Kramer BS, Black A, Gohagan JK, et al. Prolonged mortality outcomes for prostate most cancers screening within the PLCO trial with median follow-up of 15 years. Most cancers. 2017;123:592–9. https://doi.org/10.1002/cncr.30474
Siegel R, Ma J, Zou Z, Jemal A. Most cancers statistics, 2014. CA Most cancers J Clin. 2014;64:9–29. https://doi.org/10.3322/caac.21208
Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: results on threat of toxicity and most cancers. DNA Cell Biol. 1996;15:273–80. https://doi.org/10.1089/dna.1996.15.273
Hsing AW, Sakoda LC, Chua S Jr. Weight problems, metabolic syndrome, and prostate most cancers. Am J Clin Nutr. 2007;86:s843–57. https://doi.org/10.1093/ajcn/86.3.843S. Sep
Jackson MD, Walker SP, Simpson-Smith CM, Lindsay CM, Smith G, McFarlane-Anderson N, et al. Associations of whole-blood fatty acids and dietary intakes with prostate most cancers in Jamaica. Most cancers Causes Management. 2012;23:23–33.
Parkin DM, Bray F, Ferlay J, Pisani P. International most cancers statistics, 2002. CA Most cancers J Clin. 2005;55:74–108. https://doi.org/10.3322/canjclin.55.2.74
Hsing AW, Chokkalingam AP. Prostate most cancers epidemiology. Entrance Biosci. 2006;11:1388–413. https://doi.org/10.2741/1891
Mallick S, Blanchet P, Multigner L. Prostate most cancers incidence in guadeloupe, a French Caribbean archipelago. Eur Urol. 2005;47:769–72. https://doi.org/10.1016/j.eururo.2005.02.020
Pollak M. Metformin and different biguanides in oncology: advancing the analysis agenda. Most cancers Prev Res. 2010;3:1060–5. https://doi.org/10.1158/1940-6207.CAPR-10-0175
Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Affiliation between metformin use and threat of prostate most cancers and its grade. J Natl Most cancers Inst. 2013;105:1123–31. https://doi.org/10.1093/jnci/djt170
Ben Sahra I, Laurent Okay, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral impact in vitro and in vivo via a lower of cyclin D1 degree. Oncogene. 2008;27:3576–86. https://doi.org/10.1038/sj.onc.1211024
Prabhakaran S, Thirumal D, Gimbun J, Ranganathan B. Metformin-A panacea pharmaceutical agent via convergence revolution initiative. J Nat Rem. 2018;17:69–79. https://doi.org/10.18311/jnr/2017/17938
Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto Okay, Woods YL, et al. Vital position of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J. 2008;412:211–21. https://doi.org/10.1042/BJ20080557
Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, et al. Mixture remedy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell traces with distinct driver mutations. J Transl Med. 2011;9:76 https://doi.org/10.1186/1479-5876-9-76
Rozengurt E, Sinnett-Smith J, Kisfalvi Okay. Crosstalk between insulin/insulin-like development factor-1 receptors and G protein-coupled receptor signaling methods: a novel goal for the antidiabetic drug metformin in pancreatic most cancers. Clin Most cancers Res. 2010;16:2505–11. https://doi.org/10.1158/1078-0432.CCR-09-2229
Hasanvand A. Antioxidative and anti inflammatory results of metformin; a brand new look to an outdated drug. J Ren Endocrinol. 2018;4:e02.22.
Unterberger CJ, Maklakova VI, Lazar M, Arneson PD, Mcilwain SJ, Tsourkas PK, et al. GH Motion in Prostate Most cancers Cells Promotes Proliferation, Limits Apoptosis, and Regulates Most cancers-related Gene Expression. Endocrinology. 2022;163:bqac031. https://doi.org/10.1210/endocr/bqac031
Mallik R, Chowdhury TA. Metformin in most cancers. Diabetes Res Clin Pract. 2018;143:409–19. https://doi.org/10.1016/j.diabres.2018.05.023
Clements A, Gao B, Yeap SHO, Wong MKY, Ali SS, Gurney H. Metformin in prostate most cancers: two for the worth of 1. Ann Oncol. 2011;22:2556–60. https://doi.org/10.1093/annonc/mdr037
Morales DR, Morris AD. Metformin in most cancers therapy and prevention. Annu Rev Med. 2015;66:17–29. https://doi.org/10.1146/annurev-med-062613-093128
Baguley BJ, Bolam KA, Wright ORL, Skinner TL. The impact of vitamin remedy and train on cancer-related fatigue and high quality of life in males with prostate most cancers: a scientific evaluation. Vitamins. 2017;9:1003 https://doi.org/10.3390/nu9091003
Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, et al. Affiliation of diet-induced hyperinsulinemia with accelerated development of prostate most cancers (LNCaP) xenografts. J Natl Most cancers Inst. 2007;99:1793–800. https://doi.org/10.1093/jnci/djm231.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA G. Most popular reporting gadgets for systematic evaluations and meta-analyses: the PRISMA assertion. BMJ. 2020;339:b2535 https://doi.org/10.1136/bmj.b2535
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The cochrane collaboration’s instrument for assessing threat of bias in randomised trials. BMJ. 2011;343:d5928 https://doi.org/10.1136/bmj.d5928.
Stang A. Important analysis of the Newcastle-Ottawa scale for the evaluation of the standard of nonrandomized research in meta-analyses. Eur J Epidemiol. 2010;25:603–5. https://doi.org/10.1007/s10654-010-9491-z
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an rising consensus on ranking high quality of proof and power of suggestions. BMJ. 2008;336:924–6. https://doi.org/10.1136/bmj.39489.470347.AD.
Stare J, Maucort-Boulch D. Odds ratio, hazard ratio and relative threat. Metodol Zv. 1998;13:59–67.
BMJ Finest Observe (n.d.) A glossary of EBM phrases. https://bestpractice.bmj.com/information/us/toolkit/ebm-tools/a-glossary-of-ebm-terms/. Accessed 22 July 2023.
Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Affiliation of alcohol consumption with chosen heart problems outcomes: a scientific evaluation and meta-analysis. BMJ. 2011;342:d671 https://doi.org/10.1136/bmj.d671.
Zhang JYK. What’ s the Relative Danger? A way of correcting the percentages ratio in cohort research of frequent outcomes. JAMA. 1998;280:1690–91. https://doi.org/10.1001/jama.280.19.1690
Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fastened or random results meta-analysis? Frequent methodological points in systematic evaluations of effectiveness. Int J Evid Based mostly Well being. 2015;13:196–207. https://doi.org/10.1097/XEB.0000000000000065
Harrell FE Jr, Lee KL, Pollock BG. Regression fashions in scientific research: figuring out relationships between predictors and response. J Natl Most cancers Inst. 1988;80:1198–202. https://doi.org/10.1093/jnci/80.15.1198
Haidich AB. Meta-analysis in medical analysis. Hippokratia. 2010;14:29–37.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a easy, graphical take a look at. BMJ. 1997;315:629–34. https://doi.org/10.1136/bmj.315.7109.629
Azoulay L, Dell’Aniello S, Gagnon B, Pollak M, Suissa S. Metformin and the incidence of prostate most cancers in sufferers with kind 2 diabetes. Most cancers Epidemiol Biomark Prev. 2011;20:337–44. https://doi.org/10.1158/1055-9965.EPI-10-0940
However A, Wang H, Männistö S, Pukkala E, Haukka J. Assessing the impact of therapy length on the affiliation between anti-diabetic medicine and most cancers threat. PLoS ONE. 2014;9:e113162 https://doi.org/10.1371/journal.pone.0113162
Chen CB, Eurich DT, Majumdar SR, Johnson JA. Metformin and the danger of prostate most cancers throughout racial/ethnic teams: a population-based cohort research. Prostate Most cancers Prostatic Dis. 2017;20:122–6. https://doi.org/10.1038/pcan.2016.65
Currie CJ, Poole CD, Gale EA. The affect of glucose-lowering therapies on most cancers threat in kind 2 diabetes. Diabetologia. 2009;52:1766–77. https://doi.org/10.1007/s00125-009-1440-6
Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort research of pioglitazone and most cancers incidence in sufferers with diabetes. Diabetes Care. 2011;34:923–9. https://doi.org/10.2337/dc10-1067
Freedman LS, Agay N, Farmer R, Murad H, Olmer L, Dankner R. Metformin therapy amongst males with diabetes and the danger of prostate most cancers: a population-based historic cohort research. Am J Epidemiol. 2022;191:626–35. https://doi.org/10.1093/aje/kwab287
Geraldine N, Marc A, Carla T, Chantal M, Stefaan B, Welcome W, et al. Relation between diabetes, metformin therapy and the incidence of malignancies in a Belgian main care setting. Diabetes Res Clin Pr. 2012;97:331–6. https://doi.org/10.1016/j.diabres.2012.02.002
Goldberg H, Mohsin FK, Berlin A, Chandrasekar T, Wallis CJD, Klaassen Z, et al. The urged chemopreventive affiliation of metformin with prostate most cancers in diabetic sufferers. Urol Oncol. 2021;39:191.e17–191.e24. https://doi.org/10.1016/j.urolonc.2020.08.032
Häggström C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, et al. Potential research of Sort 2 diabetes mellitus, anti-diabetic medication and threat of prostate most cancers. Int J Most cancers. 2017;140:611–7. https://doi.org/10.1002/ijc.30480
Haring A, Murtola TJ, Talala Okay, Taari Okay, Tammela TL, Auvinen A. Antidiabetic drug use and prostate most cancers threat within the Finnish randomized research of screening for prostate most cancers. Scand J Urol. 2017;51:5–12. https://doi.org/10.1080/21681805.2016.1271353
Jo JK, Tune HK, Heo Y, Kim MJ, Kim YJ. Danger evaluation of metformin use in prostate most cancers: a nationwide population-based research. Ageing Male. 2023;26:2156497 https://doi.org/10.1080/13685538.2022.2156497
Kincius M, Patasius A, Linkeviciute-Ulinskiene D, Zabuliene L, Smailyte G. Lowered threat of prostate most cancers in a cohort of Lithuanian diabetes mellitus sufferers. Ageing Male. 2020;23:1333–8. https://doi.org/10.1080/13685538.2020.1766013
Koo HY, Jeong SM, Cho MH, Chun S, Shin DW, Park J. Inhabitants-wide impacts of aspirin, statins, and metformin use on prostate most cancers incidence and mortality. Sci Rep. 2021;11:16171 https://doi.org/10.1038/s41598-021-95764-3
Kowall B, Stang A, Rathmann W, Kostev Okay. No diminished threat of total, colorectal, lung, breast, and prostate most cancers with metformin remedy in diabetic sufferers: database analyses from Germany and the UK. Pharmacoepidemiol Drug Saf. 2015;24:865–74. https://doi.org/10.1002/pds.3823
Kuo YJ, Sung FC, Hsieh PF, Chang HP, Wu KL, Wu HC. Metformin reduces prostate most cancers threat amongst males with benign prostatic hyperplasia: a nationwide population-based cohort research. Most cancers Med. 2019;8:2514–23. https://doi.org/10.1002/cam4.2025
Lopez DS, Malagaris I, Polychronopoulou E, Tsilidis KK, Milani SA, Kristen Peek M, et al. Metformin and testosterone substitute remedy inversely related to hormone-associated cancers (prostate, colorectal and male breast cancers) amongst older White and Black males. Clin Endocrinol. 2022;97:792–803. https://doi.org/10.1111/cen.14803
Lehman DM, Lorenzo C, Hernandez J, Wang CP. Statin use as a moderator of metformin impact on threat for prostate most cancers amongst kind 2 diabetic sufferers. Diabetes Care. 2012;35:1002–7. https://doi.org/10.2337/dc11-1829
Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Additional exploration of the connection between insulin glargine and incident most cancers: a retrospective cohort research of older Medicare sufferers. Diabetes Care. 2011;34:1965–71. https://doi.org/10.2337/dc11-0699
Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medicine and prostate most cancers threat: a population-based case-control research. Am J Epidemiol. 2008;168:925–31. https://doi.org/10.1093/aje/kwn190
Nair-Shalliker V, Bang A, Egger S, Yu XQ, Chiam Okay, Steinberg J, et al. Household historical past, weight problems, urological components and diabetic drugs and their associations with threat of prostate most cancers analysis in a big potential research. Br J Most cancers. 2022;127:735–46. https://doi.org/10.1038/s41416-022-01827-1
Nordström T, Clements M, Karlsson R, Adolfsson J, Grönberg H. The danger of prostate most cancers for males on aspirin, statin or antidiabetic drugs. Eur J Most cancers. 2015;51:725–33. https://doi.org/10.1016/j.ejca.2015.02.003
Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, et al. Sort 2 diabetes mellitus, glycemic management, and most cancers threat. Eur J Most cancers Prev. 2014;23:134–40. https://doi.org/10.1097/CEJ.0b013e3283656394
Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, et al. Metformin use and prostate most cancers threat. Eur Urol. 2014;66:1012–20. https://doi.org/10.1016/j.eururo.2014.04.027
Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie Okay. Preliminary metformin or sulphonylurea publicity and most cancers incidence amongst sufferers with kind 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:349–57. https://doi.org/10.1111/dom.12036
Raval AD, Mattes MD, Madhavan S, Pan X, Wei W, Sambamoorthi U. Affiliation between metformin use and most cancers stage at analysis amongst aged medicare beneficiaries with preexisting kind 2 diabetes mellitus and incident prostate most cancers. J Diabetes Res. 2016;2016:2656814 https://doi.org/10.1155/2016/2656814
Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, et al. Decrease threat of most cancers in sufferers on metformin as compared with these on sulfonylurea derivatives: outcomes from a big population-based follow-up research. Diabetes Care. 2012;35:119–24. https://doi.org/10.2337/dc11-0857
Tseng CH. Diabetes and threat of prostate most cancers: a research utilizing the Nationwide Well being Insurance coverage. Diabetes Care. 2011;34:616–21. https://doi.org/10.2337/dc10-1640
Tseng CH. Metformin considerably reduces incident prostate most cancers threat in Taiwanese males with kind 2 diabetes mellitus. Eur J Most cancers. 2014;50:2831–7. https://doi.org/10.1016/j.ejca.2014.08.007
Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven Okay, et al. Metformin doesn’t have an effect on most cancers threat: a cohort research within the U.Okay. Medical Observe Analysis Datalink analyzed like an intention-to-treat trial. Diabetes Care. 2014;37:2522–32. https://doi.org/10.2337/dc14-0584
van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering brokers and the patterns of threat for most cancers: a research with the Basic Observe Analysis Database and secondary care information. Diabetologia. 2012;55:654–65. https://doi.org/10.1007/s00125-011-2390-3
Vicentini M, Ballotari P, Giorgi Rossi P, Venturelli F, Sacchettini C, Greci M, et al. Impact of various glucose-lowering therapies on most cancers incidence in kind 2 diabetes: an observational population-based research. Diabetes Res Clin Pr. 2018;143:398–408. https://doi.org/10.1016/j.diabres.2018.04.036
Wang CP, Lehman DM, Lam YF, Kuhn JG, Mahalingam D, Weitman S, et al. Metformin for decreasing racial/ethnic distinction in prostate most cancers incidence for males with kind II diabetes. Most cancers Prev Res. 2016;9:779–87. https://doi.org/10.1158/1940-6207.CAPR-15-0425
Wright JL, Stanford JL. Metformin use and prostate most cancers in Caucasian males: outcomes from a population-based case-control research. Most cancers Causes Management. 2009;20:1617–22. https://doi.org/10.1007/s10552-009-9407-y.
Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, et al. Metformin doesn’t have an effect on threat of biochemical recurrence following radical prostatectomy: outcomes from the SEARCH database. Prostate Most cancers Prostatic Dis. 2013;16:391–7. https://doi.org/10.1038/pcan.2013.48
Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, et al. Statins are related to elevated biochemical recurrence after radical prostatectomy in diabetic males however no affiliation was seen in males additionally taking metformin: outcomes from the SEARCH database. Clin Genitourin Most cancers. 2019;17:e140–e149. https://doi.org/10.1016/j.clgc.2018.09.020
Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ. Impact of metformin on prostate most cancers outcomes after radical prostatectomy. Urol Oncol. 2014;32:43.e1–7. https://doi.org/10.1016/j.urolonc.2013.05.005
Patel T, Hruby G, Badani Okay, Abate-Shen C, McKiernan JM. Medical outcomes after radical prostatectomy in diabetic sufferers handled with metformin. Urology. 2010;76:1240–4. https://doi.org/10.1016/j.urology.2010.03.059
Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI, et al. Affiliation of diabetes mellitus and metformin use with biochemical recurrence in sufferers handled with radical prostatectomy for prostate most cancers. World J Urol. 2014;32:999–1005. https://doi.org/10.1007/s00345-013-1171-7
Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident most cancers in individuals with and with out kind 2 diabetes: influence of metformin on survival. Diabetes Care. 2012;35:299–304. https://doi.org/10.2337/dc11-1313. Feb
Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin use and all-cause and prostate cancer-specific mortality amongst males with diabetes. J Clin Oncol. 2013;31:3069–75. https://doi.org/10.1200/JCO.2012.46.7043
Bashraheel SS, Kheraldine H, Khalaf S, Moustafa AA. Metformin and HER2-positive breast most cancers: mechanisms and therapeutic implications. Biomed Pharmacother. 2023;162:114676. https://doi.org/10.1016/j.biopha.2023.114676
Takhwifa F, Aninditha T, Setiawan H, Sauriasari R. The potential of metformin as an antineoplastic in mind tumors: a scientific evaluation. Heliyon. 2021;7:e06558 https://doi.org/10.1016/j.heliyon.2021.e06558
Cerezo M, Tomic T, Ballotti R, Rocchi S. Is it time to check biguanide metformin within the therapy of melanoma? Pigment Cell Melanoma Res. 2015;28:8–20. https://doi.org/10.1111/pcmr.12267
Deng D, Yang Y, Tang X, Skrip L, Qiu J, Wang Y, et al. Affiliation between metformin remedy and incidence, recurrence and mortality of prostate most cancers: proof from a meta-analysis. Diabetes Metab Res Rev. 2015;31:595–602. https://doi.org/10.1002/dmrr.2645
He Okay, Hu H, Ye S, Wang H, Cui R, Yi L. The impact of metformin remedy on incidence and prognosis in prostate most cancers: A scientific evaluation and meta-analysis. Sci Rep. 2019;9:2218 https://doi.org/10.1038/s41598-018-38285-w
Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The consequences of adiponectin and metformin on prostate and colon neoplasia contain activation of AMP-activated protein kinase. Most cancers Prev Res. 2008;1:369–75. https://doi.org/10.1158/1940-6207.CAPR-08-0081
Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic therapy with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell development. Most cancers Res. 2007;67:6745–52. https://doi.org/10.1158/0008-5472.CAN-06-4447
Zhuang Y, Miskimins WK. Cell cycle arrest in metformin handled breast most cancers cells entails activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Sign. 2008;3:18. https://doi.org/10.1186/1750-2187-3-18
Pollak M. Insulin and insulin-like development issue signalling in neoplasia. Nat Rev Most cancers. 2008;8:915–28. https://doi.org/10.1038/nrc2536.
Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D. Evaluation of signaling pathways associated to cell proliferation stimulated by insulin analogs in human mammary epithelial cell traces. Endocr Relat Most cancers. 2009;16:429–41. https://doi.org/10.1677/ERC-08-0240
Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like development components and neoplasia. Nat Rev Most cancers. 2004;4:505–18. https://doi.org/10.1038/nrc1387
Liu X, Hemminki Okay, Försti A, Sundquist Okay, Sundquist J, Ji J. Most cancers threat in sufferers with kind 2 diabetes mellitus and their kin. Int J Most cancers. 2015;137:903–10. https://doi.org/10.1002/ijc.29440
Hu MB, Liu SH, Jiang HW, Bai PD, Ding Q. Weight problems impacts the biopsy-mediated detection of prostate most cancers, significantly high-grade prostate most cancers: a dose-response meta-analysis of 29,464 sufferers. PLoS ONE. 2014;9:e106677 https://doi.org/10.1371/journal.pone.0106677
Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C, et al. Diabetes mellitus and threat of prostate most cancers: an up to date meta-analysis primarily based on 12 case-control and 25 cohort research. Acta Diabetol. 2012;49:S235–46. https://doi.org/10.1007/s00592-012-0439-5
Schäfer G. Web site-specific uncoupling and inhibition of oxidative phosphorylation by biguanides. II. Biochim Biophys Acta. 1969;172:334–7. https://doi.org/10.1016/0005-2728(69)90077-2
Amengual-Cladera E, Morla-Barcelo PM, Morán-Costoya A, Sastre-Serra J, Pons DG, Valle A, et al. Metformin: from diabetes to cancer-unveiling molecular mechanisms and therapeutic methods. Biology. 2024;13:302 https://doi.org/10.3390/biology13050302
Li XN, Bu HM, Ma XH, Lu S, Zhao S, Cui YL, et al. Glucagon-like peptide-1 analogues inhibit proliferation and enhance apoptosis of human prostate most cancers cells in vitro. Exp Clin Endocrinol Diabetes. 2017;125:91–97. https://doi.org/10.1055/s-0042-112368
Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Sort 2 diabetes mellitus and testosterone: a meta-analysis research. Int J Androl. 2011;34:528–40. https://doi.org/10.1111/j.1365-2605.2010.01117.x
Jang A, Lanka SM, Huang M, Casado CV, Caputo SA, Sweeney PL, et al. Comparability of circulating tumor DNA between African American and Caucasian sufferers with metastatic castrate-resistant prostate most cancers post-abiraterone and/or enzalutamide. Prostate. 2023;83:1028–34. https://doi.org/10.1002/professionals.24544
Shibata A, Whittemore AS. Genetic predisposition to prostate most cancers: potential explanations for ethnic variations in threat. Prostate 1997;32:65–72.
Li J, Mercer E, Gou X, Lu YJ. Ethnical disparities of prostate most cancers predisposition: genetic polymorphisms in androgen-related genes. Am J Most cancers Res. 2013;3:127–51.
